Symbols / ERNA
ERNA Chart
About
Ernexa Therapeutics Inc., a preclinical-stage company, develops induces derived mesenchymal stem cells (iMSC) therapies for the treatment of solid tumors and autoimmune disease. The company's lead product is ERNA-101, an allogenic pro-inflammatory cytokine (IL-7/IL-15) secreting iMSC for the treatment of ovarian cancer; and ERNA-102, an anti-inflammatory cytokine (IL-10) secreting iMSC for the treatment of rheumatoid arthritis. It has a license agreement with Factor Bioscience Limited. The company was formerly known as Eterna Therapeutics Inc. and changed its name to Ernexa Therapeutics in March 2025. Ernexa Therapeutics Inc. was founded in 2018 and is based in Cambridge, Massachusetts.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 8.13M |
| Enterprise Value | -139.33K | Income | -18.36M | Sales | 1.00K |
| Book/sh | 0.46 | Cash/sh | 0.39 | Dividend Yield | — |
| Payout | 0.00% | Employees | 6 | IPO | — |
| P/E | 0.01 | Forward P/E | -0.03 | PEG | — |
| P/S | 8125.53 | P/B | 0.66 | P/C | — |
| EV/EBITDA | 0.01 | EV/Sales | -139.33 | Quick Ratio | 1.49 |
| Current Ratio | 1.58 | Debt/Eq | 15.46 | LT Debt/Eq | — |
| EPS (ttm) | 56.32 | EPS next Y | -9.60 | EPS Growth | — |
| Revenue Growth | — | Earnings | 2022-11-14 16:00 | ROA | -89.29% |
| ROE | — | ROIC | — | Gross Margin | 100.00% |
| Oper. Margin | -9922.00% | Profit Margin | 0.00% | Shs Outstand | 27.09M |
| Shs Float | 5.33M | Short Float | 2.09% | Short Ratio | 0.45 |
| Short Interest | — | 52W High | 4.95 | 52W Low | 0.27 |
| Beta | 6.74 | Avg Volume | 1.14M | Volume | 3.64M |
| Target Price | — | Recom | None | Prev Close | $0.27 |
| Price | $0.30 | Change | 10.99% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
—
Mean price target
2. Current target
$0.30
Latest analyst target
3. DCF / Fair value
$-4.13
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$0.30
Low
—
High
—
Mean
—
- $ERNA stock is up 11% today. Here's what we see in our data. - Quiver Quantitative Wed, 18 Feb 2026 19
- ERNA Stock Price and Chart — NASDAQ:ERNA - TradingView Mon, 03 Nov 2025 08
- Ernexa (NASDAQ: ERNA) partners with Cellipont for cGMP scale-up of ERNA-101 in ovarian cancer - Stock Titan Wed, 29 Oct 2025 07
- Ernexa therapeutics ten percent owner Cherington buys $2m in stock - Investing.com Wed, 18 Feb 2026 02
- Market Movers | Winners: ASST, ADIL, RLYB | Losers: EAF, ERNA, ANEB - Trefis Sat, 07 Feb 2026 04
- ERNA Stock Rallies On Collaboration With Contract Manufacturer To Advance Lead Cell Therapy Into Clinical Trials - Stocktwits Wed, 29 Oct 2025 07
- Will ERNA stock deliver shareholder value - 2025 Fundamental Recap & Stock Portfolio Risk Management - mfd.ru hu, 19 Feb 2026 11
- Ernexa Therapeutics announces 1-for-15 reverse stock split - Yahoo Finance Wed, 11 Jun 2025 07
- Insider Purchase: 10% owner at $ERNA Buys 4,000,000 Shares - Quiver Quantitative Wed, 18 Feb 2026 02
- Eterna Therapeutics Completes Public Offering to Bolster Capital - TipRanks Wed, 11 Feb 2026 08
- Ernexa Announces 1-for-15 Reverse Stock Split Effective June 12 To Regain Nasdaq Compliance - Nasdaq ue, 10 Jun 2025 07
- Ernexa Therapeutics Signs Multiple Financing Agreements - TradingView Wed, 11 Feb 2026 22
- Ernexa Therapeutics stock falls after ASH meeting presentation - Investing.com Mon, 08 Dec 2025 08
- Insider Stock Purchases: February 18, 2026 - Quiver Quantitative Wed, 18 Feb 2026 18
- Ernexa Therapeutics First Half 2025 Earnings: US$2.91 loss per share (vs US$33.78 loss in 1H 2024) - Yahoo Finance Fri, 15 Aug 2025 07
Insider Transactions
| Date | Shares | Value | Url | Text | Insider | Position | Transaction | Start Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|
| 0 | 4000000 | 1220000.0 | — | Purchase at price 0.30 per share. | CHERINGTON CHARLES | Beneficial Owner of more than 10% of a Class of Security | — | 2026-02-10 00:00:00 | D |
| 1 | 30 | nan | — | — | GURROLA SANDRA M | Officer | — | 2025-06-20 00:00:00 | D |
| 2 | 21241163 | 2221826.0 | — | Purchase at price 0.10 per share. | CHERINGTON CHARLES | Beneficial Owner of more than 10% of a Class of Security | — | 2025-06-09 00:00:00 | D |
| 3 | 3768397 | 394174.0 | — | Purchase at price 0.10 per share. | CHERINGTON CHARLES | Beneficial Owner of more than 10% of a Class of Security | — | 2025-04-02 00:00:00 | D |
| 4 | 13252112 | nan | — | — | CHERINGTON CHARLES | Beneficial Owner of more than 10% of a Class of Security | — | 2024-09-24 00:00:00 | D |
| 5 | 2819546 | 1409773.0 | — | Conversion of Exercise of derivative security at price 0.50 per share. | CHERINGTON CHARLES | Beneficial Owner of more than 10% of a Class of Security | — | 2024-09-24 00:00:00 | D |
| 6 | 437 | nan | — | — | GURROLA SANDRA M | Officer | — | 2024-06-21 00:00:00 | D |
Financials
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | -4.59M | -18.60 | 752.64K | -25.64M |
| TaxRateForCalcs | 0.21 | 0.00 | 0.21 | 0.27 |
| NormalizedEBITDA | -14.28M | -19.75M | -27.59M | -26.97M |
| TotalUnusualItems | -21.84M | -186.00K | 3.58M | -94.98M |
| TotalUnusualItemsExcludingGoodwill | -21.84M | -186.00K | 3.58M | -94.98M |
| NetIncomeFromContinuingOperationNetMinorityInterest | -44.54M | -21.67M | -24.58M | -122.55M |
| ReconciledDepreciation | 1.64M | 1.12M | 497.00K | 459.00K |
| ReconciledCostOfRevenue | 96.00K | 236.00K | 0.00 | |
| EBITDA | -36.12M | -19.93M | -24.01M | -121.95M |
| EBIT | -37.76M | -21.06M | -24.50M | -122.41M |
| NetInterestIncome | -6.50M | -476.00K | -30.00K | -74.00K |
| InterestExpense | 6.75M | 614.00K | 30.00K | 74.00K |
| InterestIncome | 249.00K | 138.00K | 0.00 | |
| NormalizedIncome | -27.28M | -21.48M | -27.41M | -53.21M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -44.54M | -21.67M | -24.58M | -122.55M |
| TotalExpenses | 17.83M | 20.74M | 26.95M | 27.43M |
| RentExpenseSupplemental | 5.07M | 3.31M | 640.00K | |
| TotalOperatingIncomeAsReported | -15.67M | -21.14M | -33.22M | -113.73M |
| DilutedAverageShares | 909.80K | 354.27K | 203.40K | 144.35K |
| BasicAverageShares | 909.80K | 354.27K | 203.40K | 144.35K |
| DilutedEPS | -48.90 | -61.20 | -120.90 | -846.00 |
| BasicEPS | -48.90 | -61.20 | -120.90 | -846.00 |
| DilutedNIAvailtoComStockholders | -44.55M | -21.68M | -24.59M | -122.56M |
| NetIncomeCommonStockholders | -44.55M | -21.68M | -24.59M | -122.56M |
| PreferredStockDividends | 16.00K | 16.00K | 16.00K | 16.00K |
| NetIncome | -44.54M | -21.67M | -24.58M | -122.55M |
| NetIncomeIncludingNoncontrollingInterests | -44.54M | -21.67M | -24.58M | -122.55M |
| NetIncomeContinuousOperations | -44.54M | -21.67M | -24.58M | -122.55M |
| TaxProvision | 30.00K | -3.00K | 45.00K | 64.00K |
| PretaxIncome | -44.51M | -21.67M | -24.53M | -122.48M |
| OtherIncomeExpense | -20.76M | -520.00K | 2.44M | -94.98M |
| OtherNonOperatingIncomeExpenses | 1.09M | -334.00K | -1.14M | -1.00K |
| SpecialIncomeCharges | -20.80M | -342.00K | -6.27M | -94.98M |
| GainOnSaleOfPPE | -1.00K | -280.00K | -9.65M | |
| OtherSpecialCharges | 20.86M | 460.00K | 79.56M | |
| WriteOff | 0.00 | 5.99M | 0.00 | |
| RestructuringAndMergernAcquisition | -66.00K | -118.00K | 0.00 | 5.76M |
| GainOnSaleOfSecurity | -1.04M | 156.00K | 9.85M | |
| NetNonOperatingInterestIncomeExpense | -6.50M | -476.00K | -30.00K | -74.00K |
| InterestExpenseNonOperating | 6.75M | 614.00K | 30.00K | 74.00K |
| InterestIncomeNonOperating | 249.00K | 138.00K | 0.00 | |
| OperatingIncome | -17.25M | -20.68M | -26.95M | -27.43M |
| OperatingExpense | 17.74M | 20.51M | 26.95M | 27.43M |
| OtherTaxes | -664.00K | |||
| ResearchAndDevelopment | 4.60M | 5.92M | 10.39M | 12.71M |
| SellingGeneralAndAdministration | 13.13M | 14.59M | 16.55M | 14.72M |
| GeneralAndAdministrativeExpense | 13.13M | 14.59M | 16.55M | 14.72M |
| OtherGandA | 4.52M | 7.09M | 9.34M | 8.65M |
| InsuranceAndClaims | 497.00K | 1.14M | 1.95M | 1.13M |
| RentAndLandingFees | 5.07M | 3.31M | 640.00K | |
| SalariesAndWages | 3.04M | 3.05M | 4.63M | 4.94M |
| GrossProfit | 486.00K | -168.00K | 0.00 | |
| CostOfRevenue | 96.00K | 236.00K | 0.00 | |
| TotalRevenue | 582.00K | 68.00K | 0.00 | 0.00 |
| OperatingRevenue | 582.00K | 68.00K | 0.00 | 0.00 |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| OrdinarySharesNumber | 3.43M | 360.69K | 341.80K | 173.40K |
| ShareIssued | 3.43M | 360.69K | 341.80K | 173.40K |
| TotalDebt | 684.00K | 41.84M | 1.18M | 2.72M |
| TangibleBookValue | -344.00K | 188.00K | 10.06M | 17.47M |
| InvestedCapital | 1.70M | 9.01M | 12.11M | 25.50M |
| WorkingCapital | -586.00K | 3.03M | 6.03M | 15.09M |
| NetTangibleAssets | -343.00K | 189.00K | 10.06M | 17.47M |
| CapitalLeaseObligations | 684.00K | 35.07M | 1.18M | 2.72M |
| CommonStockEquity | 1.70M | 2.23M | 12.11M | 25.50M |
| PreferredStockEquity | 1.00K | 1.00K | 1.00K | 2.00K |
| TotalCapitalization | 1.70M | 9.01M | 12.11M | 25.50M |
| TotalEquityGrossMinorityInterest | 1.70M | 2.23M | 12.11M | 25.50M |
| StockholdersEquity | 1.70M | 2.23M | 12.11M | 25.50M |
| RetainedEarnings | -231.54M | -186.98M | -165.30M | -140.70M |
| AdditionalPaidInCapital | 232.98M | 189.19M | 177.38M | 166.19M |
| CapitalStock | 258.00K | 28.00K | 27.00K | 15.00K |
| CommonStock | 257.00K | 27.00K | 26.00K | 13.00K |
| PreferredStock | 1.00K | 1.00K | 1.00K | 2.00K |
| TotalLiabilitiesNetMinorityInterest | 3.57M | 46.90M | 10.17M | 6.02M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 630.00K | 40.33M | 2.52M | 2.34M |
| OtherNonCurrentLiabilities | 152.00K | 191.00K | 94.00K | 47.00K |
| DerivativeProductLiabilities | 1.00K | 116.00K | 331.00K | 0.00 |
| DuetoRelatedPartiesNonCurrent | 0.00 | 1.21M | 0.00 | |
| TradeandOtherPayablesNonCurrent | 0.00 | 0.00 | 0.00 | |
| NonCurrentDeferredLiabilities | 0.00 | 392.00K | 0.00 | |
| NonCurrentDeferredRevenue | 0.00 | 392.00K | 0.00 | |
| LongTermDebtAndCapitalLeaseObligation | 477.00K | 39.63M | 887.00K | 2.30M |
| LongTermCapitalLeaseObligation | 477.00K | 32.85M | 887.00K | 2.30M |
| LongTermDebt | 6.77M | 1.21M | ||
| CurrentLiabilities | 2.94M | 6.57M | 7.65M | 3.68M |
| OtherCurrentLiabilities | 363.00K | 247.00K | ||
| CurrentDeferredLiabilities | 0.00 | 190.00K | 0.00 | |
| CurrentDeferredRevenue | 0.00 | 190.00K | 0.00 | |
| CurrentDebtAndCapitalLeaseObligation | 207.00K | 2.22M | 295.00K | 426.00K |
| CurrentCapitalLeaseObligation | 207.00K | 2.22M | 295.00K | 426.00K |
| CurrentDebt | 1.75M | |||
| OtherCurrentBorrowings | 1.75M | |||
| CurrentNotesPayable | 0.00 | |||
| PensionandOtherPostRetirementBenefitPlansCurrent | 12.00K | 109.00K | 1.06M | 656.00K |
| PayablesAndAccruedExpenses | 2.72M | 4.06M | 5.93M | 2.35M |
| CurrentAccruedExpenses | 995.00K | 1.78M | 2.56M | 593.00K |
| InterestPayable | 0.00 | 176.00K | 0.00 | 0.00 |
| Payables | 1.72M | 2.27M | 3.37M | 1.75M |
| DuetoRelatedPartiesCurrent | 0.00 | 1.21M | 1.75M | 0.00 |
| TotalTaxPayable | 3.00K | 2.00K | 0.00 | |
| IncomeTaxPayable | 3.00K | 2.00K | 0.00 | |
| AccountsPayable | 1.72M | 1.07M | 1.62M | 1.75M |
| TotalAssets | 5.27M | 49.13M | 22.28M | 31.52M |
| TotalNonCurrentAssets | 2.92M | 39.53M | 8.60M | 12.76M |
| OtherNonCurrentAssets | 118.00K | 4.21M | 5.23M | 488.00K |
| NonCurrentPrepaidAssets | 488.00K | |||
| InvestmentsAndAdvances | 0.00 | 59.00K | 1.00M | |
| LongTermEquityInvestment | 0.00 | 59.00K | 1.00M | |
| GoodwillAndOtherIntangibleAssets | 2.04M | 2.04M | 2.04M | 8.03M |
| OtherIntangibleAssets | 5.99M | |||
| Goodwill | 2.04M | 2.04M | 2.04M | 2.04M |
| NetPPE | 755.00K | 33.27M | 1.27M | 3.24M |
| AccumulatedDepreciation | -172.00K | -114.00K | -32.00K | -207.00K |
| GrossPPE | 927.00K | 33.39M | 1.30M | 3.44M |
| Leases | 0.00 | 274.00K | 0.00 | 464.00K |
| OtherProperties | 698.00K | 32.82M | 1.06M | 2.83M |
| MachineryFurnitureEquipment | 229.00K | 293.00K | 240.00K | 155.00K |
| Properties | 0.00 | 0.00 | 0.00 | 0.00 |
| CurrentAssets | 2.35M | 9.60M | 13.68M | 18.77M |
| OtherCurrentAssets | 186.00K | 1.60M | 1.28M | 1.10M |
| PrepaidAssets | 1.28M | 1.10M | ||
| Receivables | 437.00K | 425.00K | 951.00K | 684.00K |
| OtherReceivables | 437.00K | 425.00K | 951.00K | 684.00K |
| AccountsReceivable | 684.00K | |||
| CashCashEquivalentsAndShortTermInvestments | 1.73M | 7.58M | 11.45M | 16.98M |
| CashAndCashEquivalents | 1.73M | 7.58M | 11.45M | 16.98M |
| CashFinancial | 1.73M | 7.58M | 11.45M | 16.98M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| FreeCashFlow | -16.20M | -20.43M | -21.27M | -23.64M |
| RepaymentOfDebt | 0.00 | -1.50M | -2.00K | -942.00K |
| IssuanceOfDebt | 5.29M | 18.00M | 0.00 | 0.00 |
| IssuanceOfCapitalStock | 1.14M | 320.00K | 19.71M | 62.52M |
| CapitalExpenditure | -369.00K | -19.00K | -297.00K | -154.00K |
| InterestPaidSupplementalData | 48.00K | 20.00K | 30.00K | 225.00K |
| IncomeTaxPaidSupplementalData | 2.00K | 4.00K | 15.00K | 1.00K |
| EndCashPosition | 1.73M | 11.67M | 15.54M | 16.98M |
| BeginningCashPosition | 11.67M | 15.54M | 16.98M | 1.63M |
| ChangesInCash | -9.94M | -3.87M | -1.44M | 15.36M |
| FinancingCashFlow | 6.26M | 16.56M | 19.58M | 61.59M |
| CashFlowFromContinuingFinancingActivities | 6.26M | 16.56M | 19.58M | 61.59M |
| NetOtherFinancingCharges | -169.00K | -251.00K | -116.00K | |
| ProceedsFromStockOptionExercised | 0.00 | 7.00K | 10.00K | |
| CashDividendsPaid | 0.00 | -16.00K | -16.00K | -8.00K |
| PreferredStockDividendPaid | 0.00 | -16.00K | -16.00K | -8.00K |
| NetPreferredStockIssuance | 1.14M | 0.00 | ||
| PreferredStockIssuance | 1.14M | 0.00 | ||
| NetCommonStockIssuance | 0.00 | 320.00K | 19.71M | 62.52M |
| CommonStockIssuance | 0.00 | 320.00K | 19.71M | 62.52M |
| NetIssuancePaymentsOfDebt | 5.29M | 16.50M | -2.00K | -942.00K |
| NetShortTermDebtIssuance | 3.89M | 0.00 | 0.00 | |
| ShortTermDebtIssuance | 3.89M | 0.00 | 0.00 | |
| NetLongTermDebtIssuance | 5.29M | 16.50M | -2.00K | -942.00K |
| LongTermDebtPayments | 0.00 | -1.50M | -2.00K | -942.00K |
| LongTermDebtIssuance | 5.29M | 18.00M | 0.00 | 0.00 |
| InvestingCashFlow | -365.00K | -19.00K | -47.00K | -22.74M |
| CashFlowFromContinuingInvestingActivities | -365.00K | -19.00K | -47.00K | -22.74M |
| NetOtherInvestingChanges | 119.00K | |||
| NetBusinessPurchaseAndSale | 0.00 | -22.71M | ||
| SaleOfBusiness | 0.00 | 147.00K | ||
| PurchaseOfBusiness | 0.00 | -22.85M | ||
| NetPPEPurchaseAndSale | -365.00K | -19.00K | -47.00K | -154.00K |
| SaleOfPPE | 4.00K | 0.00 | 250.00K | 0.00 |
| PurchaseOfPPE | -369.00K | -19.00K | -297.00K | -154.00K |
| OperatingCashFlow | -15.84M | -20.41M | -20.98M | -23.49M |
| CashFlowFromContinuingOperatingActivities | -15.84M | -20.41M | -20.98M | -23.49M |
| ChangeInWorkingCapital | -1.98M | -2.12M | 3.71M | -2.29M |
| ChangeInOtherWorkingCapital | -582.00K | 582.00K | ||
| ChangeInOtherCurrentLiabilities | -1.68M | 964.00K | -185.00K | -297.00K |
| ChangeInOtherCurrentAssets | 2.00K | 1.01M | -646.00K | 0.00 |
| ChangeInPayablesAndAccruedExpense | -1.02M | -4.65M | 4.99M | -485.00K |
| ChangeInPayable | -1.02M | -4.65M | 4.99M | -485.00K |
| ChangeInAccountPayable | 183.00K | -2.90M | 2.03M | -485.00K |
| ChangeInPrepaidAssets | 1.32M | -556.00K | -187.00K | -850.00K |
| ChangeInReceivables | -12.00K | 527.00K | -262.00K | -659.00K |
| ChangesInAccountReceivables | -659.00K | |||
| OtherNonCashItems | 5.05M | 1.22M | 214.00K | 86.30M |
| StockBasedCompensation | 1.52M | 1.24M | 2.94M | 5.24M |
| UnrealizedGainLossOnInvestmentSecurities | -1.02M | 0.00 | ||
| AssetImpairmentCharge | 0.00 | 6.76M | 0.00 | |
| DepreciationAmortizationDepletion | 1.64M | 1.12M | 497.00K | 459.00K |
| DepreciationAndAmortization | 1.64M | 1.12M | 497.00K | 459.00K |
| Depreciation | 1.64M | 1.12M | 497.00K | 459.00K |
| OperatingGainsLosses | 23.48M | -203.00K | -10.52M | 9.35M |
| GainLossOnInvestmentSecurities | 1.04M | -215.00K | -10.79M | |
| GainLossOnSaleOfPPE | 0.00 | 1.00K | 280.00K | 13.00K |
| GainLossOnSaleOfBusiness | 0.00 | 11.00K | ||
| NetIncomeFromContinuingOperations | -44.54M | -21.67M | -24.58M | -122.55M |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for ERNA
| Date | User | Asset | Broker | Type | Position Size | Entry Price | Patterns |
|---|